Key result
Intensified antithrombotic strategies for symptomatic peripheral artery disease offer various choices, but direct comparisons are difficult due to study heterogeneity.
Why the study?
Despite the widespread use of single antiplatelet therapy with aspirin or clopidogrel, the risk of adverse cardiovascular and limb events in patients with symptomatic PAD remains high, and the optimal antithrombotic therapy is still uncertain.
Do intensified antithrombotic strategies prevent adverse cardiovascular and limb events in patients with symptomatic peripheral artery disease?
Do intensified antithrombotic strategies prevent adverse cardiovascular and limb events in patients with symptomatic peripheral artery disease?
The optimal antithrombotic strategy for symptomatic PAD remains uncertain due to study heterogeneity, necessitating individualized risk-benefit assessments.
Individualized risk-benefit assessment guides antithrombotic choice in symptomatic PAD; leaves open head-to-head trials to resolve heterogeneity.
Single antiplatelet therapy with aspirin or clopidogrel is widely used in the prevention of adverse cardiovascular and limb events in patients with symptomatic peripheral artery disease (PAD). However, the risk of these events remains high, and the most optimal antithrombotic therapy for PAD is still uncertain. We conducted a literature search to identify the major clinical trials on therapeutic approaches in the prevention of adverse events in patients with PAD. This article provides an overview of the clinical trials that have evaluated the efficacy and safety of intensified antithrombotic strategies for PAD. Due to the heterogeneity of patient populations and the variable definitions of clinical outcomes used in different clinical studies, it was difficult to make direct comparisons between the study results. Although a number of choices are now available, the risk-benefit of each antithrombotic regimen for patients with PAD must be carefully considered.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) conducted a review in Symptomatic peripheral artery disease (PAD). Intensified antithrombotic strategies was evaluated. Intensified antithrombotic strategies for symptomatic peripheral artery disease offer various choices, but direct comparisons are difficult due to study heterogeneity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: